Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06162559 |
| Title | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study (TRAIN-4) |
| Acronym | TRAIN-4 |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | The Netherlands Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | NLD |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Netherlands Cancer Institute | RECRUITING | Amsterdam | 1066CX | Netherlands | Details |